Dermira, Inc.

DERM

SCOTTSDALE, Ariz., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that members of Journey Medical's management team will participate in two October 2025 investor conferences.

EMROSI's strong launch is driving Journey Medical's growth, with rapid prescription uptake, expanding prescriber base, and improved payer coverage fueling margin expansion. I see EMROSI as the primary value driver, positioning DERM for sustainable EBITDA profitability by year-end and strong long-term revenue and EPS growth potential. Key risks include Accutane's generic erosion, uncertainty in EMROSI's net revenue per script, and limited cash reserves that may require future capital raises.

DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.

SCOTTSDALE, Ariz., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or “the Company”) (Nasdaq: DERM), a commercial-stage pharmaceutical company primarily focused on selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2025 investor conferences.

SCOTTSDALE, Ariz., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company primarily focused on selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will present a corporate overview at the Emerging Growth Conference on Wednesday, August 20, 2025 at 12:35 p.m. ET. All sessions will be conducted virtually through video webcasts.

U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Wednesday.

Journey Medical Corporation (NASDAQ:DERM ) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Claude Maraoui - Founder, President, CEO & Director Jaclyn Jaffe - Senior Director of Corporate Operations Joseph M. Benesch - CFO & Corporate Controller Ramsey Alloush - COO, General Counsel & Company Secretary Conference Call Participants Mayank Mamtani - B.

Journey Medical Corporation (DERM) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.07. This compares to a loss of $0.17 per share a year ago.

S econd quarter 2025 revenues were $15.0 million Emrosi™ net sales of $2.8 million generated in first full quarter on the market The Company joined the Russell 2000® and Russell 3000® Indexes in June 2025 Company to hold conference call today at 4:30 p.m. ET to discuss the financial results and provide a business update SCOTTSDALE, Ariz.

Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.